Pfizer drops phase II-ready NASH candidate

There’s no future in store for the drug candidate targeting the liver disease, although it will still be tested against diabetes and obesity.

Photo: Carlo Allegri/Reuters/Ritzau Scanpix

GLP-1 analog danuglipron (PF-06882961) is apparently not up to par, following a phase I study in which it was tested as a treatment for NASH, or non-alcoholic steatohepatitis with liver fibrosis.

According to Pfizer’s second-quarter report released on Thursday, the development of the candidate in this indication has been discontinued.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Further reading

Related articles

Latest news

See all jobs